MY108187A - Stabilized pharmaceutical compositions comprising an hmg-coa reductase inhibitor compound - Google Patents

Stabilized pharmaceutical compositions comprising an hmg-coa reductase inhibitor compound

Info

Publication number
MY108187A
MY108187A MYPI92002266A MYPI19922266A MY108187A MY 108187 A MY108187 A MY 108187A MY PI92002266 A MYPI92002266 A MY PI92002266A MY PI19922266 A MYPI19922266 A MY PI19922266A MY 108187 A MY108187 A MY 108187A
Authority
MY
Malaysia
Prior art keywords
hmg
coa reductase
reductase inhibitor
inhibitor compound
pharmaceutical compositions
Prior art date
Application number
MYPI92002266A
Inventor
B Kabadi Mohan
Victor Vivillecchia Richard
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MY108187A publication Critical patent/MY108187A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Motor Or Generator Frames (AREA)
  • Structures Of Non-Positive Displacement Pumps (AREA)

Abstract

A PHARMACEUTICAL DOSAGE FORM COMPRISING AN HMG-COA REDUCTASE INHIBITOR COMPOUND, E.G., FLUVASTATIN SODIUM, IS DICLOSED WHICH IS STABILIZED AGAINST PH-RELATED DEGRADATION BY AN ALKALINE STABILIZING MEDIUM CAPABLE OF IMPARTING A PH OF AT LEAST 8 TO AN AQUEOUS SOLUTION OR DISPERSION OF THE COMPOSITION.
MYPI92002266A 1991-12-12 1992-12-10 Stabilized pharmaceutical compositions comprising an hmg-coa reductase inhibitor compound MY108187A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US80566791A 1991-12-12 1991-12-12

Publications (1)

Publication Number Publication Date
MY108187A true MY108187A (en) 1996-08-30

Family

ID=40794725

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI92002266A MY108187A (en) 1991-12-12 1992-12-10 Stabilized pharmaceutical compositions comprising an hmg-coa reductase inhibitor compound

Country Status (8)

Country Link
AT (1) AT401872B (en)
DE (1) DE4245089B4 (en)
HU (1) HU221849B1 (en)
MY (1) MY108187A (en)
NZ (1) NZ270729A (en)
SA (1) SA93130414B1 (en)
TW (1) TW221377B (en)
UA (1) UA39852C2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6242003B1 (en) * 2000-04-13 2001-06-05 Novartis Ag Organic compounds

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5030447A (en) * 1988-03-31 1991-07-09 E. R. Squibb & Sons, Inc. Pharmaceutical compositions having good stability

Also Published As

Publication number Publication date
DE4245089B4 (en) 2009-07-30
NZ270729A (en) 1995-11-27
UA39852C2 (en) 2001-07-16
SA93130414B1 (en) 2004-08-14
HU221849B1 (en) 2003-02-28
ATA190595A (en) 1996-05-15
AT401872B (en) 1996-12-27
HU0000790D0 (en) 2000-04-28
TW221377B (en) 1994-03-01

Similar Documents

Publication Publication Date Title
CA2085037A1 (en) Stabilized pharmaceutical compositions comprising an hmg-coa reductase inhibitor compound
RU92004564A (en) PHARMACEUTICAL COMPOSITIONS AND METHOD FOR THEIR PRODUCTION
ATE178794T1 (en) STABILIZED ORAL COMPOSITION CONTAINING THE COMPOUND CI-981 AND METHOD
DE69831868D1 (en) Antithrombosemittel
MX9601360A (en) Synergistic stabilizing mixture.
TW239126B (en)
HU9500240D0 (en) New prolin-amide derivatives and pharmaceutical compositions containing them as active component
CA2322944A1 (en) Functionalized alkyl and alkenyl side chain derivatives of glycinamides as farnesyl transferase inhibitors
EA199901100A1 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING ELETRIPTAN HEMISULPHATE AND CAFFEINE
IL105421A0 (en) Taxol derivatives
AU3262295A (en) Metalloproteinase inhibitors
YU23599A (en) Stabilized antihistamine syrup
AU1390892A (en) Agents for preserving technical materials against insects
NZ279397A (en) Mercaptoacetylamido 1,3,4,5-tetrahydro-benzo[c]azepin-3-one disulfide derivatives and pharmaceutucal compositions
MX9602861A (en) Synergistic stabilizing mixture.
AU1705392A (en) Substituted diaminophthalimides and analogues
CA2037975A1 (en) 5-hydroxy-2,3-dihydrobenzofuran analogs as leukotriene biosynthesis inhibitors
IL136100A0 (en) Biphenylamidine derivatives, prodrugs thereof and pharmaceutical compositions containing the same
HUT62583A (en) Process for producing new tetrazole derivatives and pharmaceutical compositions comprising such compounds
MY108187A (en) Stabilized pharmaceutical compositions comprising an hmg-coa reductase inhibitor compound
CA2127374A1 (en) Novel derivative of isoindolinone, its preparation and pharmaceutical compositions containing it
AU6893994A (en) Pharmaceutical compositions
HRP20010885B1 (en) Ethanesulfonyl-piperidine derivatives
AU1600495A (en) Novel indane-2-mercaptoacetylamide disulfide derivatives useful as inhibitors of enkephalinase
NO944309D0 (en) Process for the preparation of ribonucleotide reductase inhibitors